HC ACL folks
A review of the January ACL statement about the Phase 3 trial results and an examination of other publicly available data for colorectal cancer drug trial results; and recent FDA approvals, suggests to me that if the Russian patient results were excluded - the ACL HyACT drug produced better PFS & OS results than recent FDA approvals? I'm not aware of any VALID reasons why Russian trial patients should have such different results.
So; we now have a company with a market cap of about $20 million; instead of >$0.5 billion if Phase 3 had been 'successful'.
And, we have Mylan buying Arixtra and the authorised fonda generic for >US$220 million. So; the ACL fonda asset has to be worth ????
So; 6 cents/share seems all 'very strange' to me.
- Forums
- ASX - By Stock
- All Very Strange
HC ACL folks A review of the January ACL statement about the...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable